Corneal toxicity reported with mirvetuximab soravtansine
by Elana GotkineFor patients receiving mirvetuximab soravtansine (MIRV) treatment for primary gynecologic malignancies, corneal toxicity is not uncommon, but usually resolves, according to a study pre
Updated on: October 30,2024
Corneal toxicity reported with mirvetuximab soravtansine
by Elana GotkineFor patients receiving mirvetuximab soravtansine (MIRV) treatment for primary gynecologic malignancies, corneal toxicity is not uncommon, but usually resolves, according to a study pre
Updated on:October 30,2024
